Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03031730
Title MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
UCHealth University of Colorado Hospital Aurora Colorado 80045 United States Details
NYP/Weill Cornell Medical Center New York New York 10065 United States Details
University of Texas at Austin Austin Texas 78712 United States Details
M D Anderson Cancer Center Houston Texas 77030 United States Details
University of Texas Health Science Center at San Antonio San Antonio Texas 78229 United States Details
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field